In cancer, constitutive activation of Nrf2—due to mutations in KEAP1, NRF2, or associated regulatory components—confers survival advantages by enhancing antioxidant capacity, promoting metabolic flexibility, and supporting therapy resistance. Here, NFE2L2 is linked to cancer.